6891.Two
6891.TWO is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.
Business. 6891.TWO is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6891.TWO is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.
The company's capital structure is characterized by a high proportion of equity, with total equity of TWD 155.08 billion and total liabilities of TWD 34.53 billion, resulting in a debt-to-equity ratio of 0.19. The company maintains a strong liquidity position, with cash and equivalents amounting to TWD 69.86 billion, and a current ratio of 13.58, indicating a robust ability to meet short-term obligations. However, the company is currently unprofitable, with a net loss of TWD 18.15 billion and an operating loss of TWD 17.46 billion, resulting in a negative return on equity of -11.71% and a negative return on assets of -9.57%.
The company's financial performance is significantly below the industry median for profitability metrics. The negative return on equity and return on assets suggest poor capital efficiency and operational performance. The company's price-to-book ratio of 7.25 and price-to-tangible-book ratio of 7.25 indicate that the market is valuing the company's equity at a premium relative to its book value, despite the current unprofitability. The enterprise value to revenue ratio of 851.09 is extremely high, suggesting that the market is placing a very high valuation on the company's revenue, which may not be justified by its current earnings performance.
The company's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no specific geographic breakdown provided. This lack of diversification may expose the company to higher risk if the segment or region experiences a downturn. The absence of detailed segment or geographic data limits the ability to assess the company's exposure to different markets.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The company reported a significant net loss and negative operating income, which may indicate challenges in scaling operations or achieving profitability. The capital expenditure of TWD 432.04 billion suggests a high level of investment in infrastructure or expansion, but the negative free cash flow of TWD 581.40 billion indicates that the company is not generating sufficient cash to fund these investments internally.
The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating and net income, combined with high capital expenditures, may increase the risk of future dilution if the company needs to raise additional capital to fund operations or growth initiatives. The absence of dilution sources in the risk assessment suggests that the company has not disclosed any immediate plans for equity issuance or other dilutive actions.
Recent events, as reflected in the financial snapshot, include a significant net loss and negative operating income, which may be indicative of operational challenges or market pressures. The company's high capital expenditures and negative free cash flow suggest that it is investing heavily in growth, but the lack of profitability may raise concerns about the sustainability of these investments. The absence of specific recent filings or transcripts limits the ability to assess the company's strategic direction or management commentary.
- The company has a strong liquidity position with a current ratio of 13.58 and TWD 69.86 billion in cash and equivalents.
- The company is currently unprofitable, with a net loss of TWD 18.15 billion and an operating loss of TWD 17.46 billion.
- The company's valuation metrics, such as the price-to-book ratio of 7.25 and enterprise value to revenue ratio of 851.09, suggest a high market valuation despite current unprofitability.
- The company's capital expenditures are significant, but the negative free cash flow indicates that it is not generating sufficient internal cash to fund these investments.
- The company's risk profile is characterized by low liquidity and dilution risk, but the lack of profitability and high capital expenditures may increase the risk of future dilution.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 6891.TWO Market data — financials · 2026-05-27